HemoSonics, LLC is breaking new ground in point-of-care Viscoelastic #hemostasis testing. When time is critical, the Quantra® QPlus® System offers rapid, accurate, and easy to understand results that enable clinicians to make more informed #transfusion decisions, more quickly. This novel, cartridge-based POC VET system now has De Novo marketing authorization in the USA and is intended to assess the coagulation status of perioperative patients at the point of care.

Information Technology

HemoSonics

Robert A. Roda

Kevin Gibson

Sydney Schiff

Todd Allen

Alexander Johnson

W. Sue Hamlett

MacKenzie Newton

Shaun Winnail

Joseph A. Steele

John Friedl

Mark C. Hennessy

Deborah O. Sinclair

Bruce D. Spiess

Deborah Winegar

Raymond L Szafranski Jr

Francesco Viola

Joe Steele

The Leadership Team at HemoSonics drives the strategic vision and operational goals of the company, focusing on advancing point-of-care hemostasis testing. This team, composed of key executives including the CEO, CFO, and VPs of Clinical Affairs and Research & Development, works collaboratively to ensure the successful development and commercialization of innovative products like the Quantra® QPlus® System, ultimately enhancing clinical decision-making and patient outcomes in perioperative settings.

Leadership Team

Clinical and Medical Team

Engineering Team

Scientific and Development Team

Leadership Team

About

Team members

Other teams at HemoSonics

Clinical and Medical Team

Engineering Team

Scientific and Development Team